{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T05:09:33Z","timestamp":1736658573320,"version":"3.32.0"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T00:00:00Z","timestamp":1160438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:p><jats:bold>Abstract: Background\/Aim:<\/jats:bold>Pegylated interferon (Peg\u2010IFN) plus ribavirin is the standard therapy for hepatitis C. Peg\u2010IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect. Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Both drugs are associated with adverse reactions of different magnitudes. Autoimmune phenomena have been reported with this treatment. In this paper, we describe cases of ALT\/GGT flares during Peg\u2010IFN plus ribavirin treatment, which related to the appearance of anti\u2010Golgi antibody and disease progress.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>We investigated three patients with hepatitis C and severe ALT\/GGT flares during Peg\u2010IFN and ribavirin treatment coinciding with anti\u2010Golgi complex antibody as the only marker of autoimmunity. We then reviewed the medical files and tested anti\u2010Golgi antibody in stored sera from 25 patients treated with conventional IFN and in 14 patients treated with Peg\u2010IFN.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>The three patients were male, over 45 years of age; all were relapsers and non\u2010responders. Anti\u2010Golgi antibody was positive during treatment coinciding with ALT\/GGT flares but with hepatitis C virus (HCV)\u2010RNA negativity, disappearing after stopping treatment, with normalization of ALT\/AST levels. One patient had progression of fibrosis from F2 to F3 despite negativity of HCV\u2010RNA. In the last group, only two patients treated with Peg\u2010IFN experienced ALT\/GGT flares but without anti\u2010Golgi antibody<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold>The presence of anti\u2010Golgi complex antibody could be a marker of a temporary autoimmune phenomenon and progressive disease.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2006.01345.x","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T19:07:02Z","timestamp":1160507222000},"page":"1148-1154","source":"Crossref","is-referenced-by-count":6,"title":["Anti\u2010Golgi complex antibodies during pegylated\u2010interferon therapy for hepatitis C"],"prefix":"10.1111","volume":"26","author":[{"given":"Raymundo","family":"Paran\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Isabel","family":"Schinoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz A. R.","family":"De Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Codes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilton","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Trepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10,10]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(02)01649-0"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410802"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904223401602"},{"issue":"1","key":"e_1_2_4_5_2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff L B.","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_4_6_2","first-page":"369","article-title":"Extrahepatic manifestations of HCV infection","volume":"31","author":"Zinego A L","year":"1999","journal-title":"facts and controversies"},{"key":"e_1_2_4_7_2","unstructured":"CliffordB D DonahueD SmithL et al.High prevalence of serological markers of autoimmunity in patients chronic hepatitis C Hepatol 1997;26:561\u201362002; 136: 747\u201357."},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-10-200205210-00010"},{"key":"e_1_2_4_9_2","first-page":"3","article-title":"Consensus statements","volume":"31","author":"EASL International Consensus Conference on Hepatitis C.","year":"1999","journal-title":"J Hepatol"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80042-X"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50218"},{"key":"e_1_2_4_12_2","first-page":"1672","article-title":"Induction of antinuclear antibody after interferon therapy in patients with hepatitis type\u2010C infection","volume":"41","author":"Noda K","year":"1996","journal-title":"its relation to the efficacy of therapy"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02087923"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(04)95201-3"},{"issue":"6","key":"e_1_2_4_15_2","first-page":"284","article-title":"Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin","volume":"4","author":"Parana R","year":"2000","journal-title":"Braz J Infect Dis"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200103000-00015"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2000.02114.x"},{"key":"e_1_2_4_18_2","first-page":"958","article-title":"Pegintereferon alpha 2b plus Ribavirin compared with interferon alpha 2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns M P","year":"2001","journal-title":"a randomized trial"},{"key":"e_1_2_4_19_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alpha2a (40Kd) plus Ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Freid M W","year":"2002","journal-title":"N Engl J Med"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00394-9"},{"key":"e_1_2_4_21_2","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy for hepatitis C and their management","volume":"36","author":"Fried M V.","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2004.025403"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G144"},{"key":"e_1_2_4_24_2","first-page":"579","article-title":"Anti\u2010Golgi complex autoantibodies in a patient with Sjogren syndrome and lymphoma","volume":"49","author":"Rodriguez J L","year":"1982","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"e_1_2_4_25_2","first-page":"332","article-title":"Four patients in Singapore with anti\u2010Golgi antibodies","volume":"32","author":"Mohan T C","year":"1991","journal-title":"Singapore Med J"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32525"},{"key":"e_1_2_4_27_2","first-page":"771","article-title":"Autoantibodies to Golgi proteins in hepatocellular carcinoma","volume":"14","author":"Mozo L","year":"2002","journal-title":"case report and literature review"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10367"},{"key":"e_1_2_4_29_2","first-page":"312","article-title":"Effect of alpha\u2010interferon treatment in patients with hepatitis B e antigen\u2010positive chronic hepatitis B","volume":"119","author":"Wong D K H","year":"1993","journal-title":"a meta-analysis"},{"key":"e_1_2_4_30_2","first-page":"702A","article-title":"Single dose safety\/tolerability and pharmacokinetic\/pharmacodynamics (PK\/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEG\u2010IFN) and interferon alfa\u20102a (INF alfa\u20102a) to healthy subjects","volume":"28","author":"Xu Z X","journal-title":"Hepatology"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2005.06.010"},{"issue":"7","key":"e_1_2_4_32_2","first-page":"865","article-title":"Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C","volume":"141","author":"Hurst E A","year":"2005","journal-title":"a case report and review of the literature"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00196169"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)90018-2"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2006.01345.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2006.01345.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T10:16:23Z","timestamp":1736590583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2006.01345.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,10]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.1478-3231.2006.01345.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2006.01345.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"type":"print","value":"1478-3223"},{"type":"electronic","value":"1478-3231"}],"subject":[],"published":{"date-parts":[[2006,10,10]]}}}